September 29, 2015 Off

Eli Lilly, Incyte: positive top-line results of RA-BEGIN

By Dino Mustafić

Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).

September 28, 2015 Off

Cyramza Phase II study meets its primary endpoint

By Dino Mustafić

Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.